[HTML][HTML] Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei… - The Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
[引用][C] Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei, C Krepler… - Journal of Clinical …, 2016 - cir.nii.ac.jp
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
G Zhang, DT Frederick, L Wu, Z Wei… - Journal of Clinical …, 2016 - search.ebscohost.com
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAF< sup> V600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAF< sup> V600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei… - Journal of Clinical …, 2016 - go.gale.com
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei… - Journal of Clinical …, 2016 - ohsu.elsevierpure.com
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
G Zhang, DT Frederick, L Wu, Z Wei… - The Journal of …, 2016 - europepmc.org
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei… - Journal of Clinical …, 2016 - pure.johnshopkins.edu
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei… - Journal of Clinical …, 2016 - researchwith.njit.edu
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAF V600E melanoma. This approach is not curative, as some BRAF-mutated …
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
G Zhang, DT Frederick, L Wu, Z Wei, C Krepler… - Journal of Clinical …, 2016 - hub.hku.hk
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …